Arrowhead Pharmaceuticals Current Deferred Revenue Over Time
| ARWR Stock | USD 18.54 0.26 1.42% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arrowhead Pharmaceuticals Performance and Arrowhead Pharmaceuticals Correlation. Arrowhead |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (4.65) | Revenue Per Share 0.17 | Quarterly Revenue Growth (0.94) | Return On Assets (0.41) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Arrowhead Pharmaceuticals and related stocks such as Wave Life Sciences, CytomX Therapeutics, and Assembly Biosciences Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WVE | 219 K | 219 K | 219 K | 219 K | 152 K | 591 K | 2.7 M | 2.7 M | 100.9 M | 89.7 M | 91.6 M | 37.1 M | 31.6 M | 150.1 M | 157.6 M |
| CTMX | 857 K | 857 K | 857 K | 857 K | 6.1 M | 6.1 M | 20.3 M | 40.6 M | 52.7 M | 51.4 M | 74.9 M | 69.3 M | 121.3 M | 132.3 M | 138.9 M |
| ASMB | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.1 M | 6.4 M | 9 M | 2.7 M | 2.7 M | 30.9 M | 32.5 M |
| BMRN | 2.2 M | (77.8 M) | (77.8 M) | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 13 M | 152 K | 7 M | 711 K | 4.6 M | 4.9 M |
| INCY | 24 M | 69.3 M | 66.1 M | 12.9 M | 12.9 M | 12.5 M | 191.1 M | 259 M | 226.4 M | 312.4 M | 448.9 M | 617 M | 457.9 M | 1 B | 1.1 B |
| IONS | 22.7 M | 36.6 M | 35.9 M | 48.1 M | 54.6 M | 67.3 M | 51.3 M | 106.5 M | 160.3 M | 118 M | 108 M | 98 M | 91 M | 151.1 M | 158.7 M |
| APLS | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 103.2 M | 103.2 M | 92.9 M | 86.1 M |
| PRQR | 46 K | 46 K | 46 K | 46 K | 468 K | 144 K | 347 K | 347 K | 545 K | 711 K | 700 K | 5.1 M | 5.8 M | 20.6 M | 21.6 M |
| ANNX | 391 K | 391 K | 391 K | 391 K | 391 K | 391 K | 391 K | 391 K | 391 K | 391 K | 391 K | 9.2 M | 9.2 M | 10.6 M | 11.2 M |
| DAWN | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 6.6 M | 25.5 M | 29.3 M | 30.8 M |
| BPMC | 1 M | 1 M | 1 M | 1 M | 3.9 M | 5.9 M | 11.4 M | 5.4 M | 3.6 M | 6.2 M | 12.6 M | 36.6 M | 448.6 M | 812 K | 771.4 K |
Arrowhead Pharmaceuticals and related stocks such as Wave Life Sciences, CytomX Therapeutics, and Assembly Biosciences Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Arrowhead Pharmaceuticals | ARWR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 18.54
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.